Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074827 | 0.92 | HDAC1 (0.64) | HDAC1KCNH2 | |
| SCHEMBL5110889 | 0.91 | HDAC1 (0.53) | HDAC1KCNH2TRPV1LMNACYP1A2 | |
| SCHEMBL12772662 | 0.91 | HDAC1 (0.49) | HDAC1KCNH2TRPV1 | |
| SCHEMBL5106201 | 0.89 | HDAC1 (0.53) | HDAC1KCNH2TRPV1LMNACYP1A2 | |
| SCHEMBL2076346 | 0.89 | HDAC1 (0.47) | HDAC1KCNH2TRPV1LMNACYP1A2 | |
| SCHEMBL2077508 | 0.82 | HDAC1 (0.64) | HDAC1KCNH2 | |
| SCHEMBL5797598 | 0.82 | HDAC1 (0.60) | HDAC1KCNH2TRPV1 | |
| SCHEMBL12772660 | 0.81 | HDAC1 (0.49) | HDAC1KCNH2TRPV1LMNACYP1A2 | |
| SCHEMBL2075893 | 0.81 | HDAC1 (0.64) | HDAC1KCNH2 | |
| SCHEMBL15480525 | 0.80 | HDAC1 (0.68) | HDAC1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293687-A1 | Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| WO-2006024841-A2 | BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293687-A1 | Benzamide Compounds | HDAC1, HDAC11, HDAC2 | HDAC1 1/4885KCNH2 1027/4885TRPV1 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.